Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 11/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 7/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ARRB1 | P49407 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL15501048 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13076870 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2997 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL5183254 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13696339 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8049464 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13154676 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL7987114 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL10820235 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636272-B2 | Method and composition for inhibiting virus infection | Arjil Biotech Holding Company Limited (TW) | 2026-05-26 | — | — | US | disclosed |
| US-12606529-B2 | Sulfur and amide tropolone inhibitors of nucleotidyl transferases and uses therefor | SAINT LOUIS UNIVERSITY (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3886579-B2 | EX VIVO ORGAN TREATMENT WITH PEG-PHOSPHOLIPID MOLECULES | ICOAT MEDICAL AB (SE) | 2025-12-24 | — | — | EP | disclosed |
| US-20250177448-A1 | NEW USE OF PEG-PHOSPHOLIPID MOLECULES | ICOAT MEDICAL AB (SE) | 2025-06-05 | — | — | US | disclosed |
| WO-2025029561-A2 | VACCINE CONTAINING RBD2 OF CDTB COMPONENT FROM BINARY TOXIN CDT OF CLOSTRIDIOIDES DIFFICILE | UNIVERSITY OF SOUTH FLORIDA (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-4490272-A1 | NEW USE OF PEG-PHOSPHOLIPID MOLECULES | iCoat Medical AB (SE) | 2025-01-15 | — | — | EP | disclosed |
| US-20250000878-A1 | COMPOSITION, FORMULATIONS AND METHODS OF MAKING AND USING BOTANICALS AND NATURAL COMPOUNDS FOR THE PROMOTION OF HEALTHY BRAIN AGING | THE BRAIN HEALTH PROJECT, LLC | 2025-01-02 | — | — | US | disclosed |
| EP-3307255-B1 | INHIBITORS OF NUCLEOTIDYL TRANSFERASES AND USE IN HERPES AND HEPATITIS VIRAL INFECTIONS THEREFOR | UNIV SAINT LOUIS (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024233921-A1 | COMPOSITIONS FOR THE TRANSTYMPANIC DELIVERY OF ANTIBIOTICS AND METHODS FOR USING THE SAME | CORNELL UNIVERSITY (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-118900913-A | New use of PEG-phospholipid molecule | 爱科特医药公司 | 2024-11-05 | — | — | CN | disclosed |
| US-20100221339-A1 | Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts | PHOENUX AG (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100221339-A1 | Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts | PHOENUX AG (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100190728-A1 | Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090012110-A1 | MORPHINE COMPOUNDS FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITATSKLINIKUM FREIBURG (DE) | 2009-01-08 | — | — | US | disclosed |
| US-20080319519-A1 | METHOD AND DEVICE FOR PATIENT TEMPERATURE CONTROL EMPLOYING OPTIMIZED REWARMING | ZOLL CIRCULATION, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080206883-A1 | HPLC METHOD FOR SEPARATION AND DETECTION OF HYDROMORPHONE AND RELATED OPIOID PHARMACOPHORES | CODY LABORATORIES, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080206883-A1 | HPLC METHOD FOR SEPARATION AND DETECTION OF HYDROMORPHONE AND RELATED OPIOID PHARMACOPHORES | CODY LABORATORIES, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-7351254-B2 | Method and device for patient temperature control employing optimized rewarming | INNERCOOL THERAPIES, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7189254-B2 | Method and device for patient temperature control employing optimized rewarming | INNERCOOL THERAPIES, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070042999-A1 | Phosphate derivatives of pharmaceutical products | VITAL HEALTH SCIENCES PTY. LTD (AU) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042999-A1 | Phosphate derivatives of pharmaceutical products | S100P, PTMS, ALPP | OPRM1 21/4885OPRD1 78/4885OPRK1 53/4885 |
| US-20250177448-A1 | NEW USE OF PEG-PHOSPHOLIPID MOLECULES | PLTP, PHOSPHO1, CD47 | OPRM1 1202/4885OPRD1 2879/4885OPRK1 3606/4885 |
| US-20100190728-A1 | Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885OPRD1 4/4885OPRK1 1/4885 |
| US-20100221339-A1 | Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-12636272-B2 | Method and composition for inhibiting virus infection | HAVCR2, CD4, ICOS | OPRM1 340/4885OPRD1 40/4885OPRK1 762/4885 |
| US-20090012110-A1 | MORPHINE COMPOUNDS FOR PHARMACEUTICAL COMPOSITIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-12606529-B2 | Sulfur and amide tropolone inhibitors of nucleotidyl transferases and uses therefor | GARS1, PNP, AARS1 | OPRM1 2798/4885OPRD1 2241/4885OPRK1 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.